Literature DB >> 1515704

Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain.

F Akai1, S Hiruma, T Sato, N Iwamoto, M Fujimoto, M Ioku, S Hashimoto.   

Abstract

FPF1070 is an aqueous protein-free solution, which consists of 85% free amino acids and 15% small peptides. Our previous study showed a potent neurotrophic factor-like activity in cultured embryonic cells of dorsal root ganglia. The present study investigated whether FPF1070 regenerated the cholinergic cells in the medial septal nucleus after axonal transections by cutting the fimbria-fornix. Fimbrial transection reduced the number of septal cholinergic cells by 30 +/- 3.6%, compared with the number on contralateral sides at 4 weeks. Intraperitoneal injections of FPF1070 caused 49.9 +/- 6.3% of the cholinergic neurons to survive. Furthermore, the cell sizes of the cholinergic neurons were significantly different: 16.4 +/- 4.2 microns, 14.3 +/- 3.8 microns in FPF1070 treatment and vehicle treatment, respectively. These results indicated that FPF1070 prevents the degeneration and atrophy of impaired cholinergic neurons by systemic administration.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1515704

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  12 in total

1.  N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions.

Authors:  M Windisch; B Hutter-Paier; E Grygar; E Doppler; H Moessler
Journal:  J Neural Transm (Vienna)       Date:  2005-03-07       Impact factor: 3.575

2.  Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I-a randomized, placebo-controlled, double-blind, Asian-Pacific trial.

Authors:  W Poon; C Matula; P E Vos; D F Muresanu; N von Steinbüchel; K von Wild; V Hömberg; E Wang; T M C Lee; S Strilciuc; J C Vester
Journal:  Neurol Sci       Date:  2019-09-07       Impact factor: 3.307

3.  Spotlight on cerebrolysin in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

4.  Ameliorative influence of a nootropic drug on motor activity of rats after bilateral carotid artery occlusion.

Authors:  A Gschanes; V Valousková; M Windisch
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Reinnervation of the rat musculocutaneous nerve stump after its direct reconnection with the C5 spinal cord segment by the nerve graft following avulsion of the ventral spinal roots: a comparison of intrathecal administration of brain-derived neurotrophic factor and Cerebrolysin.

Authors:  P Haninec; P Dubový; F Sámal; L Houstava; L Stejskal
Journal:  Exp Brain Res       Date:  2004-09-04       Impact factor: 1.972

6.  Reductions in qEEG slowing over 1 year and after treatment with Cerebrolysin in patients with moderate-severe traumatic brain injury.

Authors:  X Antón Alvarez; Carolina Sampedro; Jesús Figueroa; Iván Tellado; Andrés González; Manuel García-Fantini; Ramón Cacabelos; Dafin Muresanu; Herbert Moessler
Journal:  J Neural Transm (Vienna)       Date:  2008-02-14       Impact factor: 3.575

Review 7.  Cerebrolysin: a review of its use in dementia.

Authors:  Greg L Plosker; Serge Gauthier
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

8.  In vitro models of brain ischemia: the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death.

Authors:  Birgit Gutmann; Birgit Hutter-Paier; Gerhard Skofitsch; Manfred Windisch; Rudolf Gmeinbauer
Journal:  Neurotox Res       Date:  2002-02       Impact factor: 3.911

9.  Efficacy and safety of Cerebrolysin in patients with hemorrhagic stroke.

Authors:  O Bajenaru; C Tiu; H Moessler; F Antochi; D Muresanu; B O Popescu; Philipp Novak
Journal:  J Med Life       Date:  2010 Apr-Jun

10.  Cerebrolysin for vascular dementia.

Authors:  Shuhui Cui; Ning Chen; Mi Yang; Jian Guo; Muke Zhou; Cairong Zhu; Li He
Journal:  Cochrane Database Syst Rev       Date:  2019-11-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.